Eli Lilly reported a 55.5% revenue increase to $19.80B in Q1 2026, driven by obesity drugs Mounjaro and Zepbound, while Pfizer's revenue rose 5.4% to $14.45B, supported by Eliquis and oncology products but weighed down by declining COVID-related sales. Lilly's FDA approval of Foundayo, the first oral GLP-1 pill, strengthens its market lead, whereas Pfizer is investing $7B in obesity assets to catch up. Lilly raised its full-year guidance, signaling strong growth momentum, while Pfizer focuses on stabilizing its portfolio and extending patent exclusivity. Investors see Lilly as a growth play and Pfizer as an income option due to its dividend yield.
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
The High Court of Justice of England and Wales has approved Eli Lilly's acquisition of Centessa Pharmaceuticals for $38 per share plus potential milestone payments, valuing the deal at about $7.8 billion. The transaction will close on June 24, 2026, ...
Eli Lilly has become the first healthcare company to reach a $1 trillion market valuation, fueled by strong sales of its weight loss drugs like Mounjaro and Zepbound. The company reported a 55.5% revenue increase year-over-year to $19.8 billion in th...
Eli Lilly's board has declared a dividend of $1.73 per share for the third quarter of 2026, payable on September 10 to shareholders recorded by August 14. This dividend reflects the company's ongoing commitment to returning value to shareholders amid...
BioArctic has entered a research collaboration with Eli Lilly to develop a new neurodegenerative disease treatment using BioArctic's BrainTransporter technology combined with a Lilly drug candidate. BioArctic will receive $30 million upfront and coul...
